We read with interest the TULIP-LTE study by Vibeke Strand and colleagues1 evaluating the long-term effect of anifrolumab on patient-reported outcomes in patients with systemic lupus erythematosus (SLE). Although the results provide valuable insights into health-related quality of life, the absence of information on antimalarial use during the 4-year follow-up is notable, given its clinical relevance. Antimalarials, particularly hydroxychloroquine, are a cornerstone of the management of SLE, with proven benefits on disease activity, flares, organ protection, and long-term survival.
The Lancet